---
title: "Sinopharm posts unaudited Q1 2026 figures, highlighting RMB 400.8bn asset base"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284128644.md"
description: "Sinopharm Group Co. Ltd. has released its unaudited financial results for Q1 2026, reporting an asset base of approximately RMB 400.8 billion. The update reveals current assets of RMB 356.1 billion, driven by increased accounts receivables and inventories, while non-current assets remain stable at RMB 44.7 billion. This disclosure enhances transparency for investors and demonstrates compliance with reporting standards. The latest analyst rating for Sinopharm's stock (HK:1099) is a Buy, with a price target of HK$22.50."
datetime: "2026-04-27T00:08:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284128644.md)
  - [en](https://longbridge.com/en/news/284128644.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284128644.md)
---

# Sinopharm posts unaudited Q1 2026 figures, highlighting RMB 400.8bn asset base

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Sinopharm Group Co ( (HK:1099) ) just unveiled an update.

Sinopharm Group Co. Ltd. has released unaudited consolidated and standalone financial information for the three months ended 31 March 2026, prepared under PRC GAAP, as required by regulators in the mainland and Hong Kong. The disclosure covers balance sheets, income statements and cash flow statements for the group and the parent company, highlighting a substantial asset base of about RMB 400.8 billion and indicating continued large-scale operations in pharmaceutical distribution.

The quarterly figures show current assets rising to roughly RMB 356.1 billion, driven by higher accounts receivables and inventories, while non-current assets remained broadly stable around RMB 44.7 billion. This update enhances transparency for bond and equity investors by providing an early snapshot of Sinopharm’s 2026 financial position, and underscores the group’s compliance with cross-border reporting standards as it manages liquidity, credit exposure and growth in China’s healthcare market.

The most recent analyst rating on (HK:1099) stock is a Buy with a HK$22.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.

**More about Sinopharm Group Co**

Sinopharm Group Co. Ltd. is a major pharmaceutical distributor and healthcare services provider in China, operating through a network of subsidiaries with listings in Hong Kong and on mainland exchanges. The group focuses on wholesale and retail distribution of medicines and medical supplies, as well as related healthcare logistics and services across the domestic market.

**YTD Price Performance:** -1.13%

**Average Trading Volume:** 5,686,485

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$59.98B

Find detailed analytics on 1099 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [01099.HK](https://longbridge.com/en/quote/01099.HK.md)

## Related News & Research

- [Sinopharm Group Co (SHTDF) Gets a Buy from CLSA](https://longbridge.com/en/news/284466436.md)
- [Sinopharm Group (SEHK:1099): Valuation Check After Renewing Shanghai Henlius Distribution Partnership](https://longbridge.com/en/news/269631888.md)
- [Herbal Dispatch Completes Company Record 500kg Medical Cannabis Export Shipment to Europe | LUFFF Stock News](https://longbridge.com/en/news/286883156.md)
- [Totaligent Closes Strategic Acqui-Hire of Aetherium Medical Platform | TGNT Stock News](https://longbridge.com/en/news/287061134.md)
- [Arctaris Impact Launches Workforce Housing Project in Downtown Lima to Support Healthcare Professionals, Working Families](https://longbridge.com/en/news/287094503.md)